ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
Revive Therapeutics Ltd (QB)

Revive Therapeutics Ltd (QB) (RVVTF)

0.0085
0.00015
(1.80%)
終了 12月2日 6:00AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
0.0085
買値
0.007
売値
0.0307
出来高
34,548
0.0069 日の範囲 0.0095
0.0055 52 週間の範囲 0.036
時価総額
前日終値
0.00835
始値
0.0082
最終取引時間
財務取引量
US$ 297
VWAP
0.008598
平均取引量 (3 か月)
483,366
発行済株式数
418,564,269
配当利回り
-
PER
-0.75
1 株当たり利益 (EPS)
-0.01
歳入
-
純利益
-5.62M

Revive Therapeutics Ltd (QB) について

セクター
Pharmaceutical Preparations
業界
Unit Inv Tr, Closed-end Mgmt
ウェブサイト
本社
Toronto, Ontario, Can
設立
2014
Revive Therapeutics Ltd (QB) is listed in the Pharmaceutical Preparations sector of the その他OTC with ticker RVVTF. The last closing price for Revive Therapeutics (QB) was US$0.01. Over the last year, Revive Therapeutics (QB) shares have traded in a share price range of US$ 0.0055 to US$ 0.036.

Revive Therapeutics (QB) currently has 418,564,269 shares in issue. The market capitalisation of Revive Therapeutics (QB) is US$3.50 million. Revive Therapeutics (QB) has a price to earnings ratio (PE ratio) of -0.75.

RVVTF 最新ニュース

Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

  Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19   TORONTO, Canada -- April 18, 2022 -- InvestorsHub NewsWire -- Revive...

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

  Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19   TORONTO, Canada -- April 12, 2022 -- InvestorsHub NewsWire -- Revive...

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19   Expected to seek DSMB approval to proceed with EUA application to the FDA in...

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

                              HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive...

Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

 Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation  TORONTO, February 15, 2022 -- Revive...

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to...

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 701 subjects dosed to date Initiating enrollment activities in Turkey as part of its...

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

 Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film...

Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

 Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19 Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment...

Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

 Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant TORONTO, November 16, 2021 -- InvestorsHub NewsWire -- Revive...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1000.00850.00980.00652868280.00744905CS
40.0020431.57894736840.006460.0120.0065389060.00798769CS
120.00033.658536585370.00820.0120.00554833660.00706545CS
26-0.0115-57.50.020.020.00553632060.00873635CS
52-0.01475-63.44086021510.023250.0360.00553529310.01559635CS
156-0.3885-97.85894206550.3970.4406610.00554456220.12360477CS
260-0.0115-57.50.020.720.005510677150.2786705CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
EVOLSymbolic Logic Inc (CE)
US$ 0.99
(98,999,900.00%)
600
CRMBQCrumbs Bake Shop Inc (CE)
US$ 0.012
(1,199,900.00%)
15.64k
GPDBGreen PolkaDot Box Incorporated (CE)
US$ 0.0002
(19,900.00%)
21.54k
FCGDFirst Colombia Gold Corporation (PK)
US$ 0.0001
(9,900.00%)
600k
BIIOBionovate Technologies Corporation (CE)
US$ 0.0001
(9,900.00%)
1.21k
TIHETaihe Group Inc (CE)
US$ 0.000001
(-100.00%)
1
SBBGSeibels Bruce Group Inc (CE)
US$ 0.000001
(-100.00%)
4
MXLGFMX Gold Corporation (CE)
US$ 0.000001
(-100.00%)
1.1k
VIVEViveve Medical Inc (CE)
US$ 0.000001
(-99.75%)
652
SMGISMG Industries Inc (CE)
US$ 0.000001
(-99.50%)
10k
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.00275
(0.00%)
51.06M
GTEHGenTech Holdings Inc (CE)
US$ 0.000001
(0.00%)
48.25M
HMBLHUMBL Inc (PK)
US$ 0.0002
(-33.33%)
42.65M
CBGLCannabis Global Inc (PK)
US$ 0.00015
(50.00%)
41.81M
GTVHGolden Triangle Ventures Inc (PK)
US$ 0.0008
(33.33%)
41.61M

RVVTF Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock